You are here
Nasal Spray for Epilepsy Seizure Gets the Axe
Diazepam spray doesn’t measure up to rectal gel
May 20, 2016
Acorda Therapeutics has announced that it will discontinue the development of Plumiaz (diazepam) nasal spray, an investigational therapy being studied for the treatment of seizure clusters in patients with epilepsy. Data from the ongoing clinical trials failed to demonstrate the product’s bioequivalence to Diastat AcuDial (diazepam) rectal gel (Valeant), which was needed to refile a new drug application (NDA) for Plumiaz.
Specifically, the data demonstrated unexpectedly lower nasal mucosa absorption of diazepam in patients with epilepsy compared with studies in healthy volunteers.
Plumiaz was granted orphan drug status from the FDA in July 2012, and Acorda submitted an NDA in 2013. In May 2014, the FDA issued a complete response letter, which informed Acorda that the application could not be approved in its present form.
In May 2015, the company announced that it would conduct three new clinical trials in participants ranging in age from 12 to 65 years. Pending the successful completion of these studies, the company planned to resubmit its NDA for Plumiaz in the first quarter of 2017.
Epilepsy is a neurological condition that produces seizures affecting a variety of mental and physical functions. Seizures occur when a brief, strong surge of electrical activity affects a part or all of the brain.
Of the approximately 2.8 million people in the United States with epilepsy, it is estimated that about 175,000 experience cluster seizures, also known as acute repetitive seizures or bouts of increased seizure activity. These patients may experience cluster seizures even though they are receiving stable regimens of antiepileptic medications. Currently, many of these individuals default to emergency room care or no care at all, according to Acorda.
Sources: Acorda Therapeutics; May 20, 2016; Acorda Therapeutics; May 2, 2014; and Plumiaz; 2016.
Despite older, sicker patients, mortality rate fell by a third in 10 years
Study finds fewer than half of trials followed the law
WHO to meet tomorrow to decide on international public heath emergency declaration
Study of posted prices finds wild variations and missing data
Potential contamination could lead to supply chain disruptions
Declining lung cancer mortality helped fuel the progress
Kinase inhibitor targets tumors with a PDGFRA exon 18 mutation
Delayed surgery reduces benefits; premature surgery raises risks
Mortality nearly doubled when patients stopped using their drugs